Chordoma

Comprehensive Clinical Guide: Chordoma

1. Introduction and Overview

Chordoma is a rare, slow-growing, locally aggressive malignant bone tumor that arises from the remnants of the embryonic notochord. While histologically characterized as low-grade, its anatomical predilection for the axial skeleton—specifically the skull base and the sacrococcygeal region—renders it clinically challenging and potentially life-threatening.

As a clinical specialist, it is imperative to recognize that chordoma is not merely a "bone tumor" but a complex neuro-oncological and orthopedic entity. Because these tumors often involve critical structures such as the brainstem, cranial nerves, spinal cord, and major vascular bundles, surgical resection is frequently complex, and the potential for local recurrence remains the primary driver of morbidity.

2. Deep-Dive: Etiology and Pathophysiology

The Notochordal Origin

The notochord is a primitive axial structure that serves as the scaffold for the developing vertebral column. While the notochordal tissue typically regresses during fetal development, residual nests of cells can persist within the vertebral bodies or the clivus. It is from these quiescent embryonic remnants that chordomas arise, typically in adulthood.

Molecular Pathogenesis

The most significant molecular hallmark of chordoma is the brachyury (T) gene. Brachyury is a transcription factor essential for notochordal development. Research has consistently demonstrated that:
* Brachyury Overexpression: Almost 100% of chordomas exhibit nuclear expression of brachyury, which serves as a highly sensitive and specific diagnostic marker.
* Genomic Instability: Deletions on chromosome 1p and 9p are frequently observed, alongside the loss of the CDKN2A/B tumor suppressor gene locus.
* Tuberous Sclerosis Complex (TSC) Pathway: Activation of the mTOR pathway has been identified as a potential therapeutic target, particularly in recurring or metastatic disease.

3. Clinical Staging and Histopathological Classification

Chordomas are categorized into three main histological subtypes, which dictate clinical behavior and prognosis.

Staging Systems

The Enneking system is traditionally used for musculoskeletal tumors, but for chordoma, clinicians often rely on the TNM Classification (AJCC), which accounts for primary tumor size, nodal involvement, and distant metastasis (most commonly to lungs, bone, and liver).

4. Standard Clinical Presentation

Presentation is entirely dependent on the anatomical location of the tumor. Because chordomas grow slowly, symptoms are often insidious, delaying diagnosis by months or even years.

• Skull Base (Clival) Chordomas:
  • Diplopia (cranial nerve VI palsy is common).
  • Headaches and facial pain/numbness (CN V involvement).
  • Dysphagia or hoarseness (lower cranial nerve involvement).
• Sacrococcygeal Chordomas:
  • Chronic low back or sacral pain.
  • Palpable presacral mass on digital rectal examination.
  • Bowel or bladder dysfunction (late-stage compression).
  • Radiculopathy or paresthesia in the lower extremities.

5. Diagnostic Methodology and Imaging

Imaging Protocols

1. Magnetic Resonance Imaging (MRI): The gold standard. Chordomas are hyperintense on T2-weighted sequences and demonstrate "honeycomb" or "septated" enhancement patterns after gadolinium administration.
2. Computed Tomography (CT): Essential for evaluating bone destruction and the presence of intratumoral calcifications (often sequestra of destroyed bone).
3. PET/CT: Increasingly used to assess metabolic activity and identify distant metastasis in dedifferentiated variants.

Histopathology

The presence of physaliferous cells—large cells with vacuolated cytoplasm containing glycogen—is pathognomonic. Immunohistochemistry must confirm the expression of Brachyury, Cytokeratin, and EMA (Epithelial Membrane Antigen) to differentiate from chondrosarcoma.

6. Management Strategy: Risks and Indications

Surgical Intervention

Surgery remains the primary treatment modality. The goal is En Bloc resection with wide margins.
* Risk: In the skull base, achieving negative margins is often impossible without sacrificing cranial nerves.
* Risk: In the sacrum, surgery may necessitate a sacrectomy, resulting in permanent neurological deficits, bowel/bladder incontinence, and pelvic instability.

Radiation Therapy

Chordomas are notoriously radioresistant. High-dose radiation is required.
* Proton Beam Therapy: The preferred standard of care for unresectable or residual disease due to the ability to deliver high doses while sparing nearby critical neural structures (Bragg peak effect).

Systemic Therapy

Chemotherapy has limited efficacy for conventional chordoma. However, targeted therapies (e.g., Imatinib, Afatinib, or mTOR inhibitors) are currently utilized in clinical trials for metastatic or unresectable cases.

7. Prognosis and Long-Term Outlook

• Local Recurrence: The primary cause of treatment failure. The rate of local recurrence is high, often occurring 5–10 years after initial diagnosis.
• Survival: The 5-year survival rate is approximately 70–80%, but this drops significantly if the tumor is dedifferentiated or metastatic.
• Surveillance: Patients require lifelong MRI surveillance (every 6 months for the first 5 years, then annually) due to the risk of very late recurrence.

8. Massive FAQ Section

1. Is chordoma a form of cancer?
Yes. Although it is slow-growing, it is a malignant tumor that can invade surrounding tissues and metastasize to distant organs.

2. Is there a genetic component to chordoma?
Most cases are sporadic. However, there is a known association with the TBXT (brachyury) gene, and rare familial cases linked to TBXT duplication have been documented.

3. Why is chordoma so difficult to treat?
Its location at the base of the skull or the sacrum makes surgical access difficult. It is also inherently resistant to conventional radiation and chemotherapy.

4. What is the difference between chondrosarcoma and chordoma?
While they look similar under a microscope, chordomas stain positive for Brachyury and Cytokeratin, whereas chondrosarcomas do not.

5. Can chordoma be cured with surgery alone?
If the tumor is small and can be removed with wide, clear margins, a cure is possible. However, due to its location, most surgeries are "subtotal," requiring follow-up radiation.

6. What are the most common sites for metastasis?
The lungs are the most common site, followed by the liver, lymph nodes, and bones.

7. Does age play a role in prognosis?
Generally, younger patients have a more aggressive clinical course compared to older patients, although this is a subject of ongoing research.

8. Will I need physical therapy after sacrectomy?
Yes. Extensive physical therapy is required to manage gait changes and pelvic floor dysfunction following sacral resection.

9. Are there clinical trials for chordoma?
Yes. Because it is a rare disease, the Chordoma Foundation maintains an active registry of clinical trials involving immunotherapy and targeted kinase inhibitors.

10. How often do I need follow-up scans?
Standard protocols suggest MRI scans every 3–6 months for the first two years, followed by biannual scans for five years, and annual scans thereafter, indefinitely.

9. Clinical Summary Table

10. Conclusion for Practitioners

Chordoma management requires a multidisciplinary team approach involving neurosurgeons, orthopedic oncologists, radiation oncologists, and specialized pathologists. The "watch and wait" approach is rarely appropriate given the tumor's inevitable growth. Early referral to a high-volume sarcoma center is the single most important factor in improving patient outcomes and reducing the likelihood of local recurrence. Clinicians must maintain a high index of suspicion for patients presenting with unexplained, progressive neurological symptoms in the axial distribution.